See the DrugPatentWatch profile for tigecycline

Tigecycline, a broad-spectrum antibiotic, has had a notable impact on the antibiotic market competition due to its patent landscape. The drug, developed by Wyeth (now Pfizer), received approval from the FDA in 2005 for treating various bacterial infections. Its patent expired in 2018 [1], leading to significant changes in the market dynamics.

Before the patent expiration, Tigecycline, marketed under the brand name Tygacil, enjoyed market exclusivity, allowing Pfizer to maintain high prices and control a significant share of the antibiotic market. This exclusivity stifled competition and limited the development of generic alternatives [2].

Post-patent expiration, the market experienced an influx of generic tigecycline versions, increasing competition and driving down prices [1]. According to DrugPatentWatch.com, the entry of generic tigecycline has led to a more competitive landscape, benefiting consumers and healthcare providers with lower costs and increased accessibility [3].

Furthermore, the expiration of Tigecycline's patent has encouraged innovation in the antibiotic market. With the barriers to entry reduced, pharmaceutical companies have been motivated to invest in research and development of new antibiotics, further stimulating market competition [1].

In summary, Tigecycline's patent expiration has significantly impacted the antibiotic market competition by promoting the entry of generic alternatives, driving down prices, and fostering innovation.

Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/drugs/tigecycline.html
[2] Grabowski, H. G., & Long, M. T. (2018). Impact of generic entry on drug prices and utilization: A review of the evidence. Clinical therapy, 40(10), 1633-1644.
[3] DrugPatentWatch.com. (n.d.). Generic Drug Entry and Market Competition. Retrieved from https://www.drugpatentwatch.com/resources/generic-drug-entry-and-market-competition/